|
|
Article: Altus Pharmaceuticals Presents Positive Data from Phase I Study of ALTU-238; First Patients Dosed in Phase II Trial in Adults with Growth Hormone Deficiency.
- Article from:
- Business Wire
- Article date:
- September 28, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass. -- Altus(R) Pharmaceuticals Inc., a company which is developing protein therapies to treat gastrointestinal and metabolic diseases, today announced results from a Phase I clinical trial for ALTU-238, a long-acting crystalline formulation of recombinant human growth hormone (somatropin). The data were presented at the 7th joint meeting of the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society (ESPE/LWPES) in Lyon, France on Saturday, September 24. ALTU-238 is a novel, subcutaneously administered once-per-week formulation of recombinant human growth hormone that employs Altus' proprietary protein crystallization ...